Management of Pneumocystis pneumonia in patients with inflammatory disorders

References

• Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jirovecii) for Pneumocystis from humans. Emerg. Infect. Dis. 8, 891–896 (2002).
   PubMed Web of Science ®Google Scholar
• Morris A, Lundgren JD, Masur H et al. Current epidemiology of Pneumocystis pneumonia. Emerg. Infect. Dis. 10, 1713–1720 (2004).
   PubMed Web of Science ®Google Scholar
• Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: more patients, same risk. Arch. Intern. Med. 155, 1125–1128 (1995).
   PubMed Web of Science ®Google Scholar
• Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin. Proc. 71, 5–13 (1996).
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Siu S. Pneumocystis carinii pneumonia in patients receiving immunosuppressive drugs for dermatological diseases. Br. J. Dermatol. 141, 528–530 (1999).
   PubMed Web of Science ®Google Scholar
• Roblot F, Godet C, Le Moal G et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur. J. Clin. Microbiol. Infect. Dis. 21, 523–531 (2002).
   PubMed Web of Science ®Google Scholar
• Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 4, 780–789 (1999).
   Google Scholar
• Porges AJ, Beattie SL, Ritchlin C, Kimberly RP, Christian CL. Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia. J. Rheumatol. 19, 1191–1194 (1992).
   PubMed Web of Science ®Google Scholar
• Jarrousse B, Guillevin L, Bindi P et al. Increased risk of Pneumocystis carinii pneumonia in patients with Wegener’s granulomatosis. Clin. Exp. Rheumatol. 11, 615–621 (1993).
   PubMed Web of Science ®Google Scholar
• Godeau B, Coutant-Perronne V, Le Thi Huong D et al. Pneumocystis carinii pneumonia in the course of connective tissue diseases: report of 34 cases. J. Rheumatol. 21, 246–251 (1994).
   PubMed Web of Science ®Google Scholar
• Ognibene FP, Shelhamer JH, Hoffman GS et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener’s granulomatosis. Am. J. Respir. Crit. Care Med. 151, 795–799 (1995).
   PubMed Web of Science ®Google Scholar
• Gerrard JG. Pneumocystis carinii pneumonia in HIV-negative immunocompromised adults. Med. J. Austr. 162, 233–235 (1995).
   PubMed Web of Science ®Google Scholar
• Stenger AA, Houtman PM, Bruyn GA, Eggink HF, Pasma HR. Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis. Scand. J. Rheumatol. 23, 51–53 (1994).
   PubMed Web of Science ®Google Scholar
• Krebs S, Gibbons RB. Low-dose methotrexate as a risk factor for Pneumocystis carinii pneumonia. Mil. Med. 161, 56–60 (1996).
   Google Scholar
• Prekates A, Kyprianou T, Paniara O, Roussos C. Pneumocystis carinii pneumonia in a HIV-seronegative patient with untreated rheumatoid arthritis and CD4+ T-lymphocytopenia. Eur. Respir. J. 10, 1184–1186 (1997).
   PubMed Web of Science ®Google Scholar
• Kadoya A, Okada J, Iikuni Y, Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J. Rheumatol. 23, 1186–1188 (1996).
   PubMed Web of Science ®Google Scholar
• Bachelez H, Schremmer B, Cadranel J et al. Fulminant Pneumocystis carinii pneumonia in 4 patients with dermatomyositis. Arch. Intern. Med. 157, 1501–1503 (1997).
   PubMedGoogle Scholar
• Sowden E, Carmichael AJ. Autoimmune inflammatory disorders, systemic corticosteroids and Pneumocystis pneumonia: a strategy for prevention. BMC Infect. Dis. 4, 42 (2004).
   PubMed Web of Science ®Google Scholar
• Scott AM, Myers GA, Harms BA. Pneumocystis carinii pneumonia postrestorative proctocolectomy for ulcerative colitis: a role for perioperative prophylaxis in the cyclosporin era? Report of a case and review of the literature. Dis. Colon Rectum 40, 973–976 (1997).
   PubMed Web of Science ®Google Scholar
• Katchatourian M, Seaton TL. An unusual complication of immunosuppressive therapy in inflammatory bowel disease. Am. J. Gastroenterol. 92, 1558–1560 (1997).
   PubMed Web of Science ®Google Scholar
• Seddik M, Meliez H, Seguy D, Viget N, Cortot A, Colombel JF. Pneumocystis jirovecii (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn’s disease. Inflamm. Bowel Dis. 10, 436–437 (2004).
   PubMed Web of Science ®Google Scholar
• Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance antitumor necrosis factor-alpha therapy with infliximab for Crohn’s disease. Inflamm. Bowel Dis. 10, 657–660 (2004).
   PubMed Web of Science ®Google Scholar
• Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal antiCD20 antibody (rituximab). J. Am. Acad. Dermatol. 51, 817–819 (2004).
   PubMed Web of Science ®Google Scholar
• Crayton HE, Sundstrom WR. Pneumocystis carinii pneumonia following corticosteroid therapy for giant cell arteritis. Wis. Med. J. 90, 170–171 (1991).
   PubMedGoogle Scholar
• Hedderwick SA, Bonilla HF, Bradley SF, Kauffman CA. Opportunistic infections in patients with temporal arteritis treated with corticosteroids. J. Am. Geriatr. Soc. 45, 334–337 (1997).
   PubMed Web of Science ®Google Scholar
• Saito K, Nakayamada S, Nakano K et al. Detection of Pneumocystis carinii by DNA amplification in patients with connective tissue diseases: re-evaluation of clinical features of Pneumocystis carinii pneumonia in rheumatic diseases. Rheumatology 43, 479–485 (2004).
   PubMed Web of Science ®Google Scholar
• Takenata R, Okada H, Mizuno M. Pneumocystis carinii pneumonia in patients with ulcerative colitis. J. Gastroenterol. 39, 1114–1119 (2004).
   PubMed Web of Science ®Google Scholar
• Tai TL, O’Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology 41, 951–952 (2002).
   PubMed Web of Science ®Google Scholar
• Thomas CF, Limper AH. Pneumocystis pneumonia. N. Engl. J. Med. 350, 2487–2498 (2004).
   PubMed Web of Science ®Google Scholar
• Baumgartner RE, Durant PJ, van Gessel Y et al. Evidence for the requirement of T-cell costimulation in the pathogenesis of natural Pneumocystis carinii pulmonary infection. Microbial. Pathog. 33, 193–201 (2002).
   PubMed Web of Science ®Google Scholar
• Godeau B, Mainardi JL, Roudot-Thoraval F et al. Factors associated with Pneumocystis carinii pneumonia in Wegener’s granulomatosis. Ann. Rheum. Dis. 54, 991–994 (1995).
   PubMed Web of Science ®Google Scholar
• Viguier M, Fouere S, de la Salmoniere P et al. Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy. Medicine 82, 82–86 (2003).
   PubMed Web of Science ®Google Scholar
• Mansharamani NG, Balachandran D, Vernovsky I, Garland R, Koziel H. Peripheral blood CD4+ T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 118, 712–720 (2000).
   PubMed Web of Science ®Google Scholar
• Nevez G, Raccurt C, Vincent P, Jounieaux V, Dei-Cas E. Pulmonary colonization with Pneumocystis carinii in human immunodeficiency virus-negative patients: assessing risk with blood CD4+ T-cell counts. Clin. Infect. Dis. 29, 1331–1332 (1999).
   PubMed Web of Science ®Google Scholar
• Helweg-Larsen J, Jensen JS, Benfield T, Svendsen UG, Lundgren JD, Lundgren B. Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples. J. Clin. Microbiol. 36, 2068–2072 (1998).
   PubMed Web of Science ®Google Scholar
• Larsen HH, Huang L, Kovacs JA et al. A prospective, blinded study of quantitative touch-down polymerase chain reaction using oral-wash samples for diagnosis of Pneumocystis pneumonia in HIV-infected patients. J. Infect. Dis. 189, 1679–1683 (2004).
   PubMed Web of Science ®Google Scholar
• Pinlaor S, Mootsikapun P, Pinlaor P et al. PCR diagnosis of Pneumocystis carinii on sputum and bronchoalveolar lavage samples in immunocompromised patients. Parasitol. Res. 94, 213–218 (2004).
   PubMed Web of Science ®Google Scholar
• Flori P, Bellete B, Durand F et al. Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing Pneumocystis jiroveci pneumonia from bronchoalveolar lavage specimens. J. Med. Microbiol. 53, 603–607 (2004).
   PubMed Web of Science ®Google Scholar
• Daly KR, Koch J, Levin L, Walzer PD. Enzyme-linked immunosorbent assay and serologic responses to Pneumocystis jiroveci. Emerg. Infect. Dis. 10, 848–854 (2004).
   PubMed Web of Science ®Google Scholar
• Skelly M, Hoffman J, Fabbri M, Holzman RS, Clarkson Jr AB, Merali S. s-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia. Lancet 361, 1267–1268 (2003).
   PubMed Web of Science ®Google Scholar
• Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin. Infect. Dis. 34, 1098–1107 (2002).
   PubMed Web of Science ®Google Scholar
• Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV- infected persons – 2002. Recommendations of the Public Health Service and the Infectious Diseases Society of America. Ann. Intern. Med. 137, 435–478 (2002).
   PubMed Web of Science ®Google Scholar
• Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 33, 139–144 (2001).
   PubMed Web of Science ®Google Scholar
• Gordon SM, LaRosa SP, Kalmadi S et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin. Infect. Dis. 28, 240–246 (1999).
   PubMed Web of Science ®Google Scholar
• EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. IV: long-term management of the transplant recipient. IV. 7 infections. Pneumocystis carinii pneumonia. Nephrol. Dial. Transplant. 17, 36–39 (2002).
   PubMedGoogle Scholar
• Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995. Comparison of HIV-associated cases to other immunocompromised states. Chest 118, 704–711 (2000).
   PubMed Web of Science ®Google Scholar
• Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob. Agents Chemother. 42, 995–1004 (1998).
   PubMed Web of Science ®Google Scholar
• Chung JB, Armstrong K, Schwartz JS, Albert D. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegener’s granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum. 43, 1841–1848 (2000).
   PubMed Web of Science ®Google Scholar
• Ioannidis JPA, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylaxis regimens. Arch. Intern. Med. 156, 177–188 (1996).
   PubMed Web of Science ®Google Scholar
• Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener’s granulomatosis: extended follow-up and rate of relapse. Am. J. Med. 114, 463–469 (2003).
   PubMed Web of Science ®Google Scholar
• Arend SM, van’t Wout JW. Prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients. As long as the pros outweigh the cons. Clin. Infect. Dis. 28, 247–249 (1999).
   PubMed Web of Science ®Google Scholar
• Armstrong W, Meshnick S, Kazanjian P. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in immunocompromised patients. Microb. Infect. 2, 61–67 (2000).
   PubMed Web of Science ®Google Scholar
• Ma L, Borio L, Masur H, Kovacs JA. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J. Infect. Dis. 180, 1969–1978 (1999).
   PubMed Web of Science ®Google Scholar
• Meneau I, Sanglard D, Bille J, Hauser PM. Pneumocystis jiroveci dihydropteroate synthase polymorphism and resistance to sulfadoxine and sulfanilamide in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 48, 2610–2616 (2004).
   PubMed Web of Science ®Google Scholar
• Nahimana A, Rabodonirina M, Zanetti G et al. Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine-sulfadoxine prophylaxis in human immunodeficiency virus-positive and negative patients. J. Infect. Dis. 188, 1017–1023 (2003).
   PubMed Web of Science ®Google Scholar
• Nahimana A, Rabodonirina M, Bille J, Francioli P, Hauser PM. Mutations of Pneumocystis jiroveci dihydrofolate reductase with failure of prophylaxis. Antimicrob. Agents Chemother. 48, 4301–4305 (2004).
   PubMed Web of Science ®Google Scholar
• Cushion MT. Pneumocystis: unravelling the cloak of obscurity. Trends Microbiol. 12, 243–249 (2004).
   PubMed Web of Science ®Google Scholar
• Huang L, Crothers K, Atzori C et al. Dihydropteroate synthase gene mutations in Pneumocystis associated with resistance. Emerg. Infect. Dis. 10, 1721–1728 (2004).
   PubMed Web of Science ®Google Scholar
• Bozette SA, Sattler FR, Chiu J et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. N. Engl. J. Med. 323, 1451–1457 (1990).
   PubMed Web of Science ®Google Scholar
• El-Sadr WM, Murphy RL, McCabe Yurik T et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfalethoxazole or both. N. Engl. J. Med. 339, 1889–1895 (1998).
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Sifri CD, Fishman JA. Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients. Clin. Infect. Dis. 38, E76–E78 (2004).
   Google Scholar
• Kessl JJ, Hill P, Lange BB, Meshnick SR, Meunier B, Trumpower BL. Molecular basis for atovaquone resistance in Pneumocystis jiroveci modeled in the cytochrome bc1 complex of Saccharomyces cerevisiae. J. Biol. Chem. 279, 2817–2824 (2004).
   PubMed Web of Science ®Google Scholar
• Marras TK, Sanders K, Lipton JH, Messner HA, Conly J, Chan CK. Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogenic marrow transplantation. Transplant. Infect. Dis. 4, 66–74 (2002).
   PubMedGoogle Scholar
• Saukkonen K, Garland R, Koziel H. Aerosolized pentamidine as alternative primary prophylaxis against Pneumocystis carinii pneumonia in adult hepatic and renal transplant recipients. Chest 109, 1250–1255 (1996).
   PubMed Web of Science ®Google Scholar
• Konishi M, Yoshimoto E, Takahashi K et al. Aerosolized pentamidine prophylaxis against AIDS-related Pneumocystis carinii pneumonia and its short- and long-term effects on pulmonary function in Japanese. J. Infect. Chemother. 9, 178–182 (2003).
   PubMedGoogle Scholar
• Theus SA, Smulian AG, Steele P, Linke MJ, Walzer PD. Immunisation with the major glycoprotein of Pneumocystis carinii elicits a protective response. Vaccine 16, 1149–1157 (1998).
   PubMed Web of Science ®Google Scholar
• Fishman JA. Treatment of infection due to Pneumocystis carinii. Antimicrob. Agents Chemother. 42, 1309–1314 (1998).
   PubMed Web of Science ®Google Scholar
• Hughes WT, LaFon S, Scott J, Masur H. Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia. J. Infect. Dis. 171, 1295–1301 (1995).
   PubMed Web of Science ®Google Scholar
• Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin. Infect. Dis. 17, S416–S422 (1993).
   Google Scholar
• Smego JR, Nagar S, Maloba B, Popara M. A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. Arch. Intern. Med. 161, 1529–1533 (2001).
   PubMedGoogle Scholar
• Cushion MT, Walzer PD, Collins MS et al. Highly active anti-Pneumocystis carinii compounds in a library of novel piperazine-linked bisbenzamidines and related compounds. Antimicrob. Agents Chemother. 48, 4209–4216 (2004).
   PubMed Web of Science ®Google Scholar
• Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adults’ non-HIV Pneumocystis carinii pneumonia. Chest 113, 1215–1224 (1998).
   PubMed Web of Science ®Google Scholar
• Delclaux C, Zahar JR, Amraoui G et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: a retrospective study of 31 patients. Clin. Infect. Dis. 29, 670–672 (1999).
   PubMed Web of Science ®Google Scholar
• Zahar JR, Robin M, Azoulay E, Fieux F, Nitenberg G, Schlemmer B. Pneumocystis carinii pneumonia in critically ill patients with malignancy: a descriptive study. Clin. Infect. Dis. 35, 929–934 (2002).
   PubMed Web of Science ®Google Scholar
• Roblot F, Le Moal G, Godet C et al. Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study. J. Infect. 47, 19–27 (2003).
   PubMed Web of Science ®Google Scholar
• Rabodonirina M, Vanhems P, Couray-Targe S et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV infected patients. Emerg. Infect. Dis. 10, 1766–1773 (2004).
   PubMed Web of Science ®Google Scholar